*Purpose: Treatment data for latent tuberculosis infection (LTBI) among potential living kidney donors is scarce. The use of 12-week isoniazid (INH) and rifapentine (RPT) in living donors have not been previously reported.

*Methods: This retrospective study was performed to evaluate the prevalence of positive quantiFERON-TB Gold In-Tube (QFT-GIT) among potential living kidney donors that were screened from January 2009 to December 2017. We also assessed the regimens used to treat LTBI and whether the recipients from QFT-GIT-positive donors developed active tuberculosis (TB).

*Results: 20/189(11%) potential living kidney donors had a positive QFT-GIT. There were no differences in gender and age between those who had a positive and negative QFT-GIT [male: 7(35%) vs. 59(35%), P=0.99, and 45.3±10.5 vs. 45.9±11.7 years, P=0.81, respectively], and positive-QFT-GIT potential donors were as likely as negative donors to undergo donation [16(80%) vs. 147(87%), P=0.49]. 12-week INH/RPT was the most common regimen used followed by 4-month rifampin (Table 1). Two of the recipients from the positive-QFT-GIT donors that were not treated, received INH post-transplant (Table 2). No active TB was found in any of the recipients from QFT-GIT-positive donors [post-transplant median follow-up: 521 days (range, 82-2478)].

*Conclusions: The short-course regimens appear to be excellent options for LTBI treatment among living kidney donors and avoid delaying organ donation.

« Back to 2019 American Transplant Congress